Week in review: Salesforce and ServiceNow portals exposed for 17 months, exploited Metabase 0-day Help Net Security
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
